EUVIMEDEUVIMED entdecken
CrossrefInfokarte

In vitro activity of manogepix against Candida spp. displaying elevated echinocandin MIC results

Marisa L. Winkler, John H. Kimbrough, Samuel Edeker, Abby Klauer, Maura H. Karr, Paul Rhomberg, Mariana Castanheira

Antimicrobial Agents and Chemotherapy · 2026-11-10

DOI: 10.1128/aac.00859-26 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Fosmanogepix is the prodrug of manogepix, an antifungal agent with a novel mechanism of action targeting the cell wall anchoring protein Gwt1. Fosmanogepix is currently in a Phase 3 clinical trial for the treatment of candidemia and invasive candidiasis (CIC). Echinocandins are first-line recommendations for empiric treatment of CIC, but resistance rates are rising, particularly in Candida glabrata . Given its unique mechanism of action, manogepix might retain activity against Candida spp. isolates that are non-susceptible to echinocandins, although supporting data are limited. Here, we collected 129 Candida spp. isolates from worldwide surveillance testing between 2017 and 2024 that were either resistant or non-wild type (WT) to ≥1 echinocandin when applying the Clinical and Laboratory Standards Institute breakpoints or epidemiological cutoff values. Isolates included 74 C. glabrata , 19 C. albicans , 14 C. auris , 14 C. tropicalis , 3 C. dubliniensis , 2 C. guilliermondii , and 1 each of C. krusei , C. lusitaniae , and C. parapsilosis . Sequencing of the gene encoding the echinocandin target was performed in all isolates and 75/129 (58.1%) had ≥1 alteration in a hotspot region of FKS1 and/or FKS2. Manogepix maintained low minimum inhibitory concentrations (MICs) across all isolates with only one C. auris isolate with a MIC above the prior WT-upper limit-defined value of 0.03 mg/L. This isolate had an alteration in Tac1B but wild-type Gwt1. All isolates were WT for amphotericin B and fluconazole resistance varied depending on species from 0% to 100%. The continued clinical development of manogepix for the treatment of CIC is warranted, including against resistant isolates based on these data.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →